ATNX News and Press, Athenex Inc. From 10/25/20

Collegium Pharmaceuticals (NASDAQ: COLL) and Athenex (NASDAQ: ATNX) may not be the most popular stocks on the market in terms of media coverage, but both might just make you rich with a well-timed investment. Unlike many of their compatriots in the world of small market cap ...

BUFFALO, N.Y., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will release third q...

Regeneron reports positive outcome for Phase 3 trial of Dupixent. Voyager slumps as FDA puts hold on Huntington’s disease program. Athenex boosts TCT-T cell therapy program with PharmaEssentia collaboration. For further details see: Regeneron Reports Positive ...

Axis Therapeutics, a joint venture between Athenex (ATNX) and Xiangxue Life Sciences has entered into a research collaboration with PharmaEssentia for development of T Cell Receptor ((TCR))-T therapy in Taiwan.Under the terms of the agreement, Axis Therapeutics and PharmaEssentia will co...

BUFFALO, N.Y., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Axis Therapeutics Limited, a joint venture between Athenex, Inc. (NASDAQ: ATNX) and Xiangxue Life Sciences Limited (“XLifeSc”), focused on the research, development, and commercialization of T cell immunotherapy, today announced...

Tracking insider purchases is an overlooked but very informative strategy. It can provide undervalued stocks in the market and can make assumptions for future market returns. September's number of insider purchases was close to the historical average, indicating that insiders are not ...

Athenex Oncology launches Your Guide to Facing Metastatic Breast Cancer, a first-of-its-kind self-care resource for people living with metastatic breast cancer (MBC) Guide offers evidence-based recommendations for increasing resilience, reducing stress, maintaining proper nutrit...

Athenex (ATNX) announced that the USFDA has allowed its investigational new drug application for TCRT-ESO-A2, an autologous T cell receptor ((TCR))-T cell therapy targeting solid tumors that are NY-ESO-1 positive in HLA-A*02:01 positive patients. TCRT-ESO-A2 is similar to TAEST16001, an autol...

BUFFALO, N.Y., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the U.S. Food and Drug...

Shares of Athenex (NASDAQ: ATNX) were down by 14.3% as of 1:35 p.m. EDT on Thursday, following the company's announcement of the pricing of a public offering of common stock. With Athenex set to dilute existing shareholders, it isn't surprising that investors are selling off shares of the bi...